➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Boehringer Ingelheim
Baxter
Harvard Business School
Mallinckrodt

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PYRIDOSTIGMINE BROMIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for PYRIDOSTIGMINE BROMIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00953914 Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients Completed Hospital de Clinicas de Porto Alegre N/A 2005-03-01 The purpose of the study is to determine if pyridostigmine bromide improves heart rate variability of type 2 diabetes mellitus subjects with cardiovascular autonomic neuropathy.
NCT01765140 Treatment Use of 3,4-Diaminopyridine Available Vern C. Juel, M.D. N/A 1969-12-31 This is a continuing project to provide 3,4 diaminopyridine (DAP) under a treatment-use IND to patients with Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndrome (CMS).
NCT01855217 Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade Unknown status St. Antonius Hospital Phase 3 2013-04-01 Should the dose of sugammadex in morbid obese patients be calculated on the real body weight or the ideal body weight? To study the pharmacodynamics of sugammadex in morbidly obese patients by comparing 1 mg/kg IBW versus 1 mg/kg TBW versus placebo.
NCT01993680 Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment Active, not recruiting University of Zurich Phase 2 2012-06-01 Disabling symptoms of blood pressure dysregulation, impaired swallowing and digestion are common amongst Parkinson`s patients. So far the exact pathophysiology for this is not fully understood. There are results from pathological analyses that the autonomic nervous system is also affected by the accumulation of alpha-Synuclein and that this might even happen in very early stages of the disease process (Qualman et al., 1984; Wakabayashi et al., 1989; Wakabayashi et al., 1990; Bloch et al., 2006). Blood pressure dysregulation is a common autonomic symptom in Parkinson`s patients and treatment - currently most often achieved with Fludrocortisone - often leads to supine hypertension (Plaschke et al., 1998; Braune et al., 1999; Magerkurth et al., 2005). There are studies in patients with autonomic failure that indicate that Pyridostigmine bromide might be an alternative treatment option without causing disabling supine hypertension (Singer et al., 2003; Sandroni et al., 2005; Singer et al., 2006; Yamamoto et al., 2006). Delayed gastric emptying is also an autonomic symptom associated with Parkinson`s disease. By the elevation of the cholinergic tone with Pyridostigmine bromide the investigators also expect to alleviate symptoms of delayed gastric emptying and obstipation, possibly even facilitating the uptake of dopaminergic medication through the gut (Sadjadpour, 1983; Bharucha et al., 2008). Therefore the investigators designed a monocentric randomized, controlled, double blind, crossover phase II trial to show non-inferiority of the effect of pyridostigmine bromide vs. fludrocortisone on symptoms of autonomic dysregulation in Parkinson`s disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PYRIDOSTIGMINE BROMIDE

Condition Name

Condition Name for PYRIDOSTIGMINE BROMIDE
Intervention Trials
Neuromuscular Blockade 1
HIV Disease 1
Myasthenic Syndromes, Congenital 1
Gulf War Illness 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for PYRIDOSTIGMINE BROMIDE
Intervention Trials
HIV Infections 2
Acquired Immunodeficiency Syndrome 2
Infection 2
Hypotension, Orthostatic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for PYRIDOSTIGMINE BROMIDE

Trials by Country

Trials by Country for PYRIDOSTIGMINE BROMIDE
Location Trials
United States 5
Mexico 2
Switzerland 1
Netherlands 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for PYRIDOSTIGMINE BROMIDE
Location Trials
North Carolina 2
Tennessee 1
New York 1
New Jersey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for PYRIDOSTIGMINE BROMIDE

Clinical Trial Phase

Clinical Trial Phase for PYRIDOSTIGMINE BROMIDE
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for PYRIDOSTIGMINE BROMIDE
Clinical Trial Phase Trials
Unknown status 2
Completed 2
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for PYRIDOSTIGMINE BROMIDE

Sponsor Name

Sponsor Name for PYRIDOSTIGMINE BROMIDE
Sponsor Trials
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1
James J. Peters Veterans Affairs Medical Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for PYRIDOSTIGMINE BROMIDE
Sponsor Trials
Other 9
NIH 2
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.